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tool enables personalising therapy by analysing discordance in hormone receptor 
(HR) and Human Epidermal Growth Factor Receptor 2 (HER2) expression in CTCs 
compared to solid tumors in metastatic breast cancer patients. It is estimated that in 
total 4,41% of metastatic breast cancer patients could be treated in a more efficient 
way, leading to increase in progression free survival of 5,59 months. Increase in clini-
cal utility is expected to be the most important consequence of this implementation 
option. ConClusions: CTCtrap as a monitoring tool is expected to be of most 
value. In this stage, a more appropropiate prescription of expensive therapies can 
be administered to patients who are sensitive for these therapies.
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objeCtives: The implementation of the 2011 German health care reform (AMNOG) 
introduced pricing mechanisms which oblige newly launched patented drugs to 
undergo an early evaluation of their additional benefit by IQWiG, with a final resolu-
tion given by the G-BA. Medicines which demonstrate an incremental therapeutic 
benefit versus an appropriate therapeutic comparator – with an innovation score 
ranging from 1 to 4 – enter the preferable pricing negotiation system; those failing 
to prove benefit – a score of 5 or 6 – are relegated to the reference pricing system. 
The study aims to discern how oncology drugs, which began the process of benefit 
assessment during 2012, fared under the new system, and whether survival data 
influenced the decisions. Methods: We reviewed both IQWiG and G-BA documents 
relating to eight cancer drugs assessed during 2012 to determine whether each drug 
received a positive or negative early benefit assessment. Reasons for each specific 
decision were then investigated. Results: Of the five drugs qualifying for pricing 
negotiations, vemurafenib (Roche, Switzerland) was the only drug to demonstrate 
a statistically significant improvement in overall survival (OS) at the time of assess-
ment. It received the highest innovation score of the five qualifying drugs. For the 
three drugs not qualifying for pricing negotiations, the G-BA cited an incomplete 
dossier or issues with comparators as the reason for rejection. ConClusions: 
Although OS is considered the favoured clinical endpoint, the study results show 
that this endpoint is not always necessary to enter pricing negotiations. However, 
when OS is not proven, the G-BA often gave a positive assessment to only a small 
portion of eligible patients. Additionally, two of the qualifying drugs were orphan 
drugs, which entails exemption from the need to prove an additional benefit if 
annual sales are below EUR50 million.
PCN182
DeveloPINg PersoNalIzeD meDICINe Drugs - INCeNTIves for 
PharmaCeuTICal ComPaNIes
Noweski M.1, Hessel F.P.2, Walendzik A.1, Jahn R.1, Wasem J.1
1University of Duisburg-Essen, Essen, Germany, 2SRH University Berlin, Berlin, Germany
objeCtives: Stratification of oncology drug therapy by genetic marker diagnostics 
can reveal additional patient benefit but also might influence the development 
process of drug manufacturers. The objective of this study is to identify and describe 
the most important incentives for pharmaceutical companies to develop person-
alized medicine drugs. Methods: To describe the main factors influencing the 
decision-making process in the development of personalized medicine drugs. The 
main factors influencing the process and their priority ranking were determined by 
structured expert interviews with pharmaceutical companies, test manufacturers 
and other key stakeholders such as regulatory bodies, reimbursement decision mak-
ers and payers. Results: In contrast to small companies big international compa-
nies constantly look for suitable companion diagnostic tests to select subgroups of 
high responder. The most important key factor for market success is the extent of 
clinical efficacy in comparison with competitors respectively the current treatment 
standard. Stratification of patient populations according to treatment response or 
frequency of adverse events using biomarker is regarded to increase clinical efficacy 
of the target indication. The test performance is important due to unsolved safety 
issues although not regarded as crucial for the success of the drug. In contrast 
to other stakeholders pharmaceutical companies did not consider personalized 
medicine to relevantly decrease development costs or marketing efforts respectively 
to increase the price potential for new drugs. A low prevalence of the remaining 
patient population after testing is not seen as a factor which might lead to a stop 
of the development of a new drug by pharmaceutical companies. ConClusions: 
Genetic stratification is seen as a breakthrough in cancer therapy by pharmaceutical 
companies and physicians. Due to the current need for improvement of approval 
and reimbursement processes for personalized medicine approaches in oncology 
especially in Europe future sales are more difficult to predict.
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objeCtives: HTA bodies treat end of life (EOL) conditions differently than other 
conditions? And if so does this depend on whether they have a specific policy for 
EOL? Methods: NICE’s website was searched for single technology appraisals of 
cancer drugs evaluated between January 2009 to May 2013 for which NICE’s supple-
mentary advice for EOL treatments was accepted. The websites of other agencies – 
SMC (Scotland), TLV (Sweden), PBAC (Australia), pCODR (Canada, except Quebec) and 
INESSS (Quebec) – were searched for HTAs of the drugs deemed to have met NICE’s 
EOL criteria. A literature search was performed to identify estimated willingness-
to-pay ICER threshold values (WTP-ICER) for each agency and to determine if the 
agency has a specific EOL policy. These were compared against the final ICERs of 
the retained HTAs. Results: Seventeen drugs were identified for which NICE’s 
EOL supplementary advice was accepted. Several of these were also evaluated by 
other agencies, but only those with final ICERs below the WTP-ICER were retained: 
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objeCtives: To assess the burden of hospitalization in advanced lung cancer 
patients in the United States. Methods: Oncologists (N= 101) actively involved in 
management of advanced lung cancer in United States were invited to participate 
in a lung cancer disease specific program. Each consenting physician was asked to 
complete patient record forms for 12 advanced (stage IIIB/IV) lung cancer patients 
seen in their practice and receiving 1st, 2nd or 3rd line of therapy for advanced lung 
cancer. The study period extended from Oct- Dec 2011. Data on hospitalization that 
included reasons of hospitalization and the length of stay (LOS) over the past year 
was provided by physicians from patient records. Results: Majority of the patients 
(N= 1200) were male (56%), Caucasian (71%) and Stage IV (78%), with an average age 
of 65 years. Hospitalization records were obtained for 93% (n= 1110) of the patients 
among which 22% (n= 248) of the patients ≥ 1 hospitalization events in the previ-
ous year with an average (SD) LOS of 4 (2.4) days and a median LOS of 3 days. The 
reasons reported for the 293 hospitalization events were disease symptoms (61%), 
surgery (19%) and therapy side effects (43%). The LOS for surgery related hospitaliza-
tion (n= 57) ranged from 1-12 days (mean (SD): 6 (2.9) days; median: 5 days). Among 
disease symptoms reported as reasons for hospitalization, the most frequent were 
pain (51%), dyspnea (47%) and cough (47%) respectively. Among side effects reported 
as reasons for hospitalization anemia (25%), febrile neutropenia (21%) and fatigue 
(20%) were most frequently reported. ConClusions: Burden of hospitalization in 
advanced lung cancer patients is significant in the United States. Innovative thera-
pies with favorable side effect profile that also alleviate need for surgery and are 
effective in improving lung cancer symptoms could help significantly in decreasing 
hospitalization burden in advanced lung cancer patients.
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objeCtives: To assess oncologist perception of their country-specific health care 
reforms and the consideration of ‘Real World Evidence’ (RWE) when prescribing 
medications in the EU, US, China and Brazil. Methods: A multi-country cross-
sectional survey was conducted in top-5 EU countries (UK, Germany, Spain, France, 
Italy), US, Brazil and China in February 2013 using an online physician panel in the 
respective geographies; oncologists were randomly selected for survey participation 
to be geographically representative in each country. Surveys assessed the oncologist 
perceptions of health care reforms in their respective countries, and their considera-
tion of the following, when prescribing oncology medications: RWE on product effec-
tiveness/safety, patient quality-of-life (QoL) and product cost/patient affordability. 
Descriptive statistics are reported. Results: A total of 257 oncologists participated 
in the survey. Specialties included: medical oncology-69%, haemato-oncology-11%, 
radiation-oncology-9%, surgical-oncology-5%, gynecologic-oncology-3%, pediat-
ric-oncology-2%, other-2%. Geographic distribution of oncologists was: 5EU-36%, 
US-33%, China-17% and Brazil-14%. Overall, 40% of oncologists indicated that 
they were ‘not sure whether their country’s health care reform is heading in the 
right direction’ (5EU:39%, US:40%, China:44%, Brazil:36%); 38% indicated that they 
were ‘concerned of country’s health care reform’s implications for them and their 
practice’ (5EU:30%, US:50%, China:44%, Brazil:19%); 23% indicated that the health 
care reform ‘did not have enough focus on RWE needs and cost-effectiveness of 
medications’ ((5EU:16%, US:24%, China:37%, Brazil:19%). When prescribing oncology 
medications, consideration of following attributes ‘all the time’ differed across the 
countries (Overall/5EU/US/China/Brazil): RWE on product effectiveness and safety 
(37%/29%/38%/47%/42%), patient QoL (54%/48%/59%/42%/69%), product cost/patient 
affordability (23%/15%/20%/42%/28%). ConClusions: Across markets, a significant 
proportion of oncologists raised concerns regarding their country-specific health 
care-reforms, and between one-third and half of the oncologists reported consid-
ering RWE data while prescribing medicines. As the health care reforms evolve in 
the studied countries, its actual implications warrant closer scrutiny to alleviate 
physician concerns and improve care delivery and outcomes.
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objeCtives: Research has shown that circulating tumor cells (CTCs) in the blood 
can give valuable information about the prognosis and treatment options in oncol-
ogy. A new approach, CTC therapeutic apheresis (CTCtrap) is being developed for use 
in breast and prostate cancer. At the moment it is not clear where in the diagnostic 
track CTCtrap could be of most value. The goal of this study is to estimate the health 
impact of using CTCtrap in 1) screening for breast cancer; 2) early staging of tumors; 
and 3) therapy response monitoring. Methods: A systematic literature study and 
experts’ interviews were used to document the diagnostic track in breast cancer. 
Headroom analysis and early health economic modelling was used to estimate the 
health impact of implementing CTCtrap at the three different purposes. Results: 
Dependent on the assumption of sensitivity, the CTCtrap could decrease the total 
screening costs. Yet, it is expected that this application only has limited clinical util-
ity. In the early staging, the CTC trap can replace the currently used FDG-PET-CT. The 
CTCtrap could provide additional staging information and therapy can be selected 
more specifically, eliminating unnecessary costs. Finally, CTCtrap as a monitoring 
